ADBIOTECH (179530) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, ADBIOTECH (179530) reported revenue of 12.9 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202512.9 billion KRW-3.5 billion KRW-3.3 billion KRW[source]
202411.1 billion KRW-4.1 billion KRW-9.0 billion KRW[source]
202310.5 billion KRW-4.8 billion KRW-5.4 billion KRW[source]
202210.6 billion KRW-4.9 billion KRW2.7 billion KRW[source]
202111.8 billion KRW-1.6 billion KRW-2.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202547.2 billion KRW32.0 billion KRW15.2 billion KRW[source]
202423.1 billion KRW16.7 billion KRW6.4 billion KRW[source]
202327.7 billion KRW13.8 billion KRW13.9 billion KRW[source]
202231.0 billion KRW14.7 billion KRW16.3 billion KRW[source]
202121.1 billion KRW15.9 billion KRW5.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice